These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35154119)

  • 1. A Commercial Anti-TIF1γ ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing.
    Mulhearn B; Li D; McMorrow F; Lu H; McHugh NJ; Tansley SL
    Front Immunol; 2022; 13():804037. PubMed ID: 35154119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TIF1γ antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays.
    Labrador-Horrillo M; Martínez MA; Selva-O'Callaghan A; Trallero-Araguás E; Balada E; Vilardell-Tarrés M; Juarez C
    Ann Rheum Dis; 2012 Jun; 71(6):993-6. PubMed ID: 22294626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.
    Fujimoto M; Murakami A; Kurei S; Okiyama N; Kawakami A; Mishima M; Sato S; Seishima M; Suda T; Mimori T; Takehara K; Kuwana M
    J Dermatol Sci; 2016 Dec; 84(3):272-281. PubMed ID: 27693019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
    Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
    Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
    Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
    Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity.
    Tansley SL; Li D; Betteridge ZE; McHugh NJ
    Rheumatology (Oxford); 2020 Aug; 59(8):2109-2114. PubMed ID: 32030410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort.
    Tarricone E; Ghirardello A; Rampudda M; Bassi N; Punzi L; Doria A
    J Immunol Methods; 2012 Oct; 384(1-2):128-34. PubMed ID: 22884621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
    Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
    Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis.
    Okiyama N; Ichimura Y; Shobo M; Tanaka R; Kubota N; Saito A; Ishitsuka Y; Watanabe R; Fujisawa Y; Nakamura Y; Murakami A; Kayama H; Takeda K; Fujimoto M
    Ann Rheum Dis; 2021 Sep; 80(9):1201-1208. PubMed ID: 33811031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.
    Venalis P; Selickaja S; Lundberg K; Rugiene R; Lundberg IE
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):648-651. PubMed ID: 28704599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort.
    Tansley SL; Simou S; Shaddick G; Betteridge ZE; Almeida B; Gunawardena H; Thomson W; Beresford MW; Midgley A; Muntoni F; Wedderburn LR; McHugh NJ
    J Autoimmun; 2017 Nov; 84():55-64. PubMed ID: 28663002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies.
    Hosono Y; Sie B; Pinal-Fernandez I; Pak K; Mecoli CA; Casal-Dominguez M; Warner BM; Kaplan MJ; Albayda J; Danoff S; Lloyd TE; Paik JJ; Tiniakou E; Aggarwal R; Oddis CV; Moghadam-Kia S; Carmona-Rivera C; Milisenda JC; Grau-Junyent JM; Selva-O'Callaghan A; Christopher-Stine L; Larman HB; Mammen AL
    Ann Rheum Dis; 2023 Feb; 82(2):246-252. PubMed ID: 36008132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera.
    Cavazzana I; Fredi M; Ceribelli A; Mordenti C; Ferrari F; Carabellese N; Tincani A; Satoh M; Franceschini F
    J Immunol Methods; 2016 Jun; 433():1-5. PubMed ID: 26906088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TIF1γ antibody and the expression of TIF1γ in idiopathic inflammatory myopathies.
    Kim Y; Song KS; Sohn EH; Kang SW; Yoo IS; Shim SC; Yoo SJ; Kim J
    Int J Rheum Dis; 2019 Feb; 22(2):314-320. PubMed ID: 30398003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis.
    Aussy A; Fréret M; Gallay L; Bessis D; Vincent T; Jullien D; Drouot L; Jouen F; Joly P; Marie I; Meyer A; Sibilia J; Bader-Meunier B; Hachulla E; Hamidou M; Huë S; Charuel JL; Fabien N; Viailly PJ; Allenbach Y; Benveniste O; Cordel N; Boyer O;
    Arthritis Rheumatol; 2019 Aug; 71(8):1360-1370. PubMed ID: 30896088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation.
    Aggarwal R; Oddis CV; Goudeau D; Fertig N; Metes I; Stephens C; Qi Z; Koontz D; Levesque MC
    Rheumatology (Oxford); 2014 Mar; 53(3):433-7. PubMed ID: 24255164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Case of Dermatomyositis Along with Esophageal Cancer and Screening of Serum Transcriptional Intermediary Factor 1 Gamma Antibodies in Various Cancer Patients.
    Sumazaki M; Kaneko K; Ito M; Oshima Y; Saito F; Ogata H; Shibuya K; Shimada H
    Am J Case Rep; 2020 Apr; 21():e922004. PubMed ID: 32312948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis.
    Kotobuki Y; Tonomura K; Fujimoto M
    Immunol Med; 2021 Mar; 44(1):23-29. PubMed ID: 32649853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Combination of IgA and IgG autoantibodies against Transcriptional Intermediary Factor-1γ contributes to the early diagnosis of Lung Cancer.
    Yu L; Lin X; Zhang L; Wu Q; Zhang S; Chen D; Pan X; Huang Y
    Int J Med Sci; 2020; 17(11):1561-1568. PubMed ID: 32669959
    [No Abstract]   [Full Text] [Related]  

  • 20. ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositis.
    Selickaja S; Galindo-Feria AS; Dani L; Mimori T; Rönnelid J; Holmqvist M; Lundberg IE; Venalis P
    Rheumatology (Oxford); 2022 Nov; 61(12):4991-4996. PubMed ID: 35579337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.